Central surgical associationSurgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era☆
Section snippets
Material and methods
A retrospective chart review from March 1995 to November 2002 revealed that 57 patients who were diagnosed with GIST were either initially treated with surgery at the University of Chicago (n = 28 patients) or referred for the treatment of recurrent or metastatic disease after exploratory surgery at outside institutions (n = 29 patients). Patients were treated and followed prospectively at the University of Chicago and were entered into a clinical database in which patient information, surgical
Patient characteristics
From March 1995 to November 2002, 57 patients with a diagnosis of GIST were treated, and the cases were followed. Twenty-eight of these patients underwent surgical exploration and attempted resection at the University of Chicago. The remaining 29 patients were referred for evaluation and treatment of metastatic disease or for adjuvant treatment after surgery at outside institutions.
Patient characteristics are shown in Table I. This group of patients was comprised of 51% men and 49% women, with
Discussion
GIST represent the most common mesenchymal tumors of the gastrointestinal tract. GIST characteristically stain positive for CD117, an epitope of the KIT tyrosine kinase receptor. With the identification of an effective therapeutic agent, the tyrosine kinase inhibitor imatinib mesylate, it has become increasingly important in the clinical treatment of GIST to distinguish these neoplasms from other mesenchymal tumors such as leiomyomas, leiomyosarcomas, and schwannomas. In addition to CD117, GIST
References (16)
- et al.
Management of malignant gastrointestinal stromal tumours
Lancet Oncol
(2002) - et al.
Clinical management of gastrointestinal stromal tumors: before and after STI-571
Hum Pathol
(2002) - et al.
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study
Lancet
(2001) - et al.
Diagnosis of gastrointestinal stromal tumors: a consensus approach
Hum Pathol
(2002) - et al.
Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade
Hum Pathol
(2002) - et al.
Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review
Hum Pathol
(2002) - et al.
Neuroectodermal differentiation of the gastrointestinal tumors in the Carney triad: an ultrastructural and immunohistochemical study
Am J Surg Pathol
(1993) - et al.
Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal
Am J Pathol
(1998)
Cited by (109)
Successful excision of a giant stomach gastrointestinal stromal tumour–A case report
2024, International Journal of Surgery Case ReportsFactors affecting clinical outcomes in women with non-gastric gastrointestinal stromal tumors
2022, Taiwanese Journal of Obstetrics and GynecologyCitation Excerpt :In addition, there was no lymph node metastasis in our study (Table 1), and this finding was consistent with that of a previous study and is probably related to the unique clinical properties of spindle cells; thus, lymph node dissection should not be necessary for GIST surgical treatment [24,25], which is different from the treatment of ovarian cancer. Complete surgical resection with clear surgical margins along with adjuvant target therapy is the main treatment for GIST [26,27]. Most women with non-gastric GISTs underwent surgical intervention by general surgeons or colon/rectal surgeons; however, GISTs may mimic gynecologic malignancy, and patients with GISTs may receive surgical intervention by gynecologists or gynecologic oncologists under the preoperative diagnosis of adnexal tumor.
Surgical treatment of primary gastrointestinal stromal tumors (GISTs): Management and prognostic role of R1 resections
2020, American Journal of SurgeryImaging in Gastroenterology
2018, Imaging in GastroenterologyAn atypical presentation of gastrointestinal stromal tumour: a case report
2022, Journal of Surgical Case Reports
- ☆
Presented at the 60th Annual Meeting of the Central Surgical Association, Toronto, Ontario, Canada, March 20-22, 2003.